What matters is whether they knew it before the date of the shareholder letter which was 12/17/24. CytoDyn said they would present it if it were approved to be presented and it was approved for presentation.

But, I'm now also considering that once Madrigal learned of the results, maybe they then considered licensing leronlimab. If such a discussion took place, then that would have also behooved CytoDyn to withdraw the presentation.